The Effect of Sitagliptin in the Treatment of Type 2 Diabetic Patients with Poor Insulin Therapy
Objective:To investigate the effect of sitagliptin in the treatment of type 2 diabetes mellitus(T2DM)patients with poor insulin effect and its effect on islet B cell function.Methods:A total of 126 T2DM patients with poor insulin treatment in our hospital from July 2020 to July 2022 were selected and divided into control group and observation group according to the random number table method,with 63 cases in each group.Both groups were treated with insulin(30 U per day).The control group was treated with metformin,and the observation group was treated with sitagliptin.The blood glucose level,islet function level,blood lipid level and adverse reactions were compared between the two groups.Results:After 3 months of treatment,the fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG),insulin resistance index(HOMA-IR),total cholesterol(TC)and triglyceride(TG)in the observation group were lower than those in the control group,and the islet B cell function level(HOMA-B)was higher than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 12.69%,which was lower than 26.98%in the control group(P<0.05).Conclusion:The application of sitagliptin in T2DM patients with poor insulin treatment is helpful to improve islet B cell function,reduce blood glucose and blood lipid levels,and has fewer adverse reactions and high safety.
SitagliptinType 2 diabetes mellitusIslet B cell function
NETL
NSTL
万方数据
